Screening for SARS-CoV-2 antibodies to save vaccine doses.
作者信息
Fenollar Florence, Thomas Laurence, Raoult Didier, Gautret Philippe
机构信息
Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France; IHU-Méditerranée Infection, Marseille, France.
IHU-Méditerranée Infection, Marseille, France.
出版信息
Vaccine. 2022 May 11;40(22):2984-2985. doi: 10.1016/j.vaccine.2022.04.028. Epub 2022 Apr 12.
Abstract
摘要
相似文献
1
Screening for SARS-CoV-2 antibodies to save vaccine doses.筛查新冠病毒抗体以节省疫苗剂量。
Vaccine. 2022 May 11;40(22):2984-2985. doi: 10.1016/j.vaccine.2022.04.028. Epub 2022 Apr 12.
2
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.新型冠状病毒刺突蛋白受体结合域线性表位在 COVID-19 mRNA 疫苗接种者中的高分辨率线性表位作图。
Microbiol Spectr. 2021 Dec 22;9(3):e0096521. doi: 10.1128/Spectrum.00965-21. Epub 2021 Nov 10.
3
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.一种基于重组串联重复二聚体 RBD 的蛋白亚单位疫苗（ZF2001）在成年人中的安全性和免疫原性：两项随机、双盲、安慰剂对照、1 期和 2 期临床试验。
Lancet Infect Dis. 2021 Aug;21(8):1107-1119. doi: 10.1016/S1473-3099(21)00127-4. Epub 2021 Mar 24.
4
The level of protective post-vaccination antibodies in NIPH-NIH employees after administration of Pfizer vaccine against COVID-19.辉瑞 COVID-19 疫苗接种后日本国立感染症研究所-国立卫生研究所员工的保护性疫苗接种后抗体水平。
Przegl Epidemiol. 2021;75(1):3-13. doi: 10.32394/pe.75.01.
5
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.
6
Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.有或无前新冠病毒感染启动的情况下，SARS-CoV-2疫苗BNT162b2的抗体依赖性中和能力
J Intern Med. 2021 Dec;290(6):1272-1274. doi: 10.1111/joim.13366. Epub 2021 Aug 2.
7
Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2.灭活新冠疫苗BBV152/COVAXIN可有效中和最近出现的新冠病毒B.1.1.7变异株。
J Travel Med. 2021 Jun 1;28(4). doi: 10.1093/jtm/taab051.
8
Salivary antibodies are detected with a commercial anti-SARS-CoV-2 assay only after two doses of vaccine using serum thresholds.唾液抗体仅在使用血清阈值接种两剂疫苗后，才能通过商业 SARS-CoV-2 检测试剂盒检测到。
Clin Biochem. 2022 Jun;104:66-69. doi: 10.1016/j.clinbiochem.2022.02.002. Epub 2022 Feb 4.
9
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.智利科兴和国药疫苗接种后动态 IgG 血清阳性率：哨点监测研究。
Lancet Infect Dis. 2022 Jan;22(1):56-63. doi: 10.1016/S1473-3099(21)00479-5. Epub 2021 Sep 9.
10
Questioning the justification for a fourth SARS-CoV-2 vaccine.质疑第四剂新冠病毒疫苗的合理性。
Clin Microbiol Infect. 2022 Jul;28(7):905-907. doi: 10.1016/j.cmi.2022.03.023. Epub 2022 Mar 23.
本文引用的文献
1
Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects.既往 SARS-CoV-2 感染者的长期抗体持久性和优异的疫苗接种应答。
Vaccine. 2021 Jul 13;39(31):4256-4260. doi: 10.1016/j.vaccine.2021.06.020. Epub 2021 Jun 12.
2
Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.法国 SARS-CoV-2 抗体的流行率：全国血清学监测结果。
Nat Commun. 2021 May 21;12(1):3025. doi: 10.1038/s41467-021-23233-6.
3
Analytical performances of five SARS-CoV-2 whole-blood finger-stick IgG-IgM combined antibody rapid tests.五种 SARS-CoV-2 全血手指点刺 IgG-IgM 联合抗体快速检测试剂的分析性能。
J Virol Methods. 2021 Apr;290:114067. doi: 10.1016/j.jviromet.2021.114067. Epub 2021 Jan 18.
4
Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies.评估严重急性呼吸综合征冠状病毒2（SARS-CoV-2）血清学检测工具的性能及其在2019冠状病毒病（COVID-19）诊断策略中的定位。
Diagn Microbiol Infect Dis. 2020 Dec;98(4):115181. doi: 10.1016/j.diagmicrobio.2020.115181. Epub 2020 Aug 21.
Zotero 插件